EVGN

Collaboration combines Evogene's AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity REHOVOT, Israel and DAEJEON, South Korea, July 22, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, and ELEO Inc., a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, today announced a strategic scientific collaboration to discover and develop next-generation oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases.

New AI model enables ChemPass AI for Ag™ to identify and prioritize antifungal molecules with a higher probability of biological success  at early discovery stages REHOVOT, Israel, July 15, 2026 /PRNewswire/ -- AgPlenus Ltd., a company developing novel, sustainable crop protection products and a subsidiary of Evogene Ltd.

Supporting Israel's Academic Innovation Ecosystem: BCDD to Provide World-Class Experimental Infrastructure, Evogene to Deliver Computational Chemistry and AI Capabilities REHOVOT, ISRAEL and TEL AVIV, ISRAEL, July 8, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational chemistry company focused on the generative design of small molecules for the pharmaceutical and agricultural industries, and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University, today announced a strategic joint initiative aimed at accelerating the growth, development, and success of innovation originating from Israel's academic research ecosystem and focused on small-molecule drug discovery.

Integration of agentic computational systems enables the early-stage definition of key clinical and biological success criteria, accelerating discovery timelines, improving scalability, and increasing the likelihood of success. REHOVOT, Israel, June 24, 2026 /PRNewswire/ -- Evogene Ltd.

Conference to be held in San Diego, CA, USA – June 22-25, 2026 REHOVOT, Israel, June 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it will be featured as a presenting company at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, USA.

Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity REHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd.

EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript

Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript

Conference call and webcast: today, May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first quarter ended March 31, 2026.

Conference will be held in Munich, Germany - May 19-21, 2026 REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in the 24th Schrödinger European User Group Meeting, taking place May 19–21, 2026, in Munich, Germany.